Park Square is pleased to announce the placement of Dr. Robert Gould as an Independent Director at Faeth Therapeutics. Faeth is a data-driven, evidence-based company developing a deep mechanistic understanding of the way that dietary nutrients influence tumor growth and cancer treatments. Faeth focuses on matching specific diets with different tumor genotypes and treatments to improve cancer therapy outcomes.
Gould is a serial entrepreneur and business-builder from the biotechnology industry. He most recently served as Chief Executive Officer at Fulcrum Therapeutics, which he grew from an early-stage company to a clinical-stage, publicly traded enterprise. Prior to Fulcrum, he served as Chief Executive Officer at Epizyme, which he successfully scaled and took public. Earlier in his career he held roles of increasing responsibility at Merck, where he most recently served as Vice President, Research and Vice President, Global Licensing and External Research.
In addition to Faeth, Gould currently serves on the Board of Directors at HemoShear Therapeutics, Turnstone Biologics, and Fulcrum Therapeutics.
Gould received his BS in Chemistry from Spring Arbor University and his Ph.D. in Biochemistry from the University of Iowa. He completed his post-doctoral research in Neuropharmacology at The John Hopkins University School of Medicine.
Park Square Executive Search serves companies and institutions that are shaping the world through discovery, innovation and growth. Our clients are leading life sciences and healthcare organizations, technology companies, major research universities, and venture capital and private equity firms, including their portfolio companies. We place board members, chief executive officers, C-suite executives, and academic leaders.